Pulmonary hypertension is characterized by thickened pulmonary arterial walls due to increased number of pulmonary artery smooth muscle cells (PASMC). Apoptosis of PASMC may play important roles in regulating the PASMC number and may be useful for reducing pulmonary vascular thickening. The present study examined the regulation of an anti-apoptotic protein Bcl-x L . Bcl-x L expression was found to be increased in the pulmonary artery of chronic hypoxia treated rats with pulmonary vascular remodeling. Adenovirus-mediated gene transfer of 
Introduction
Pulmonary hypertension is characterized by the elevation of pulmonary vascular resistance, which interferes with the ejection of blood by the right ventricle and ultimately causes heart failure. It is often developed secondary to various cardiovascular and pulmonary diseases such as left ventricular failure, congenital heart defects, chronic obstructive pulmonary disease, sleep apnea syndrome and post-thrombotic diseases. Pulmonary arterial hypertension can also occur as a genetic disorder. Pulmonary hypertension is associated with increased vasoconstriction in the pulmonary circulation and vascular remodeling in part due to thickening of pulmonary vascular wall because of increased number of smooth muscle cells (SMC). While therapeutic agents are available which target the vasoconstrictive aspect of this condition, preventing or treating pulmonary vascular remodeling is also needed. Recently, apoptosis-based therapeutic strategies to reduce pulmonary vascular thickening gained attention and have been successful in experimental animals (1) (2) (3) (4) (5) . Thus, further understanding of the regulation of apoptosis in pulmonary vascular smooth muscle should promote developing therapeutic strategies to treat pulmonary hypertension.
The Bcl-2 family consists of anti-apoptotic members including Bcl-2, Bcl-x L , Bcl-w, and Ced9, while Bax, Bid, Bad, Bak and Bcl-x S belong to the pro-apoptotic group. Bcl-x plays a dual role in apoptotic regulation, using the different splicing protein products; one being antiapoptotic Bcl-x L and another being a shorter form, pro-apoptotic Bcl-x S (6) . Bcl-x L often represents the major isoform expressed in various tissues. Bcl-x S is a dominant negative repressor of Bcl-2 and Bcl-x L (7, 8) . Overexpression of Bcl-x S has been shown to enhance apoptosis of cancer cells (9) (10) (11) (12) (13) .
A series of observations suggest the role of Bcl-x L in the regulation of apoptosis in smooth muscle cells (SMC) from systemic circulation during various disease conditions. In a rabbit carotid artery balloon injury model, Bcl-x L mRNA and protein levels are upregulated in the atheromatous lesion, and the anti-sense Bcl-x L increases intimal smooth muscle apoptosis and reduces the intimal lesion size and thickness (14) . Similarly, in mouse coronary artery with arteriopathy after the cardiac allograft, antisense Bcl-x L increased intimal cell apoptosis and suppressed arterial neointimal formation (15) . Angiotensin II increases medial and neointimal apoptosis and downregulates Bcl-x L expression (16) . Regulation of Bcl-x L in pulmonary vascular smooth muscle has not been defined. Recently, neonatal rats with pulmonary hypertension were found to have increased expression of Bcl-x L in pulmonary arterial walls (17) .
Bcl-x L has also been shown to be upregulated as a cytoprotective response in hyperoxic acute lung injury (18) .
We here report that mediators of pulmonary vascular remodeling increase the expression of Bcl-x L in pulmonary artery. Bcl-x L levels can effectively be reduced by apoptotic agents such as sodium nitroprusside (SNP). SNP-mediated downregulation of Bcl-x L is dependent on the inhibition of GATA-4 gene expression in remodeled pulmonary artery. We cloned the gata4 promoter and identified the site of SNP actions. 
Methods

Culture of pulmonary artery SMC
Measurements of mitochondrial membrane potential
To measure mitochondrial membrane potential disruption, cells were grown in 12-well plates for 24 h followed by treatment with or without testing reagents for 24 h. DePsipher Kit (Trevigen Inc., Gaithersburg, MD) was used to detect changes in mitochondrial membrane potential with a cationic dye 5,5'6,6'-tetrachloro-1,1',3,3'-tetraethylbenzimidazolylcarbocyanine iodide. In accordance with the manufacture's instruction, cells were incubated for 20 min in 1x reaction buffer, stabilizing solution and DePsipher solution at 37°C. The cells were examined under a fluorescence microscope (Olympus) with a red/green dual filter cube.
Comet Assay
The neutral comet assay was used to measure double stranded DNA breaks as an indication of apoptosis. Cells were treated with apoptotic stimuli, washed in PBS, embedded in 1% agarose and placed on a comet slide (Trevigen, Gaithersburg, MD). Cells were then placed in a lysis solution (2.5 M NaCl, 1% Na-lauryl sarcosinate, 100 mM EDTA, 10 mM Tris base, 0.01% Triton X-100) for 30 min. The nuclei were subsequently electrophoresed for 20 min at 1 V/cm in 1x TBE, fixed in ethanol, followed by staining with Sybr Green and visualized with a fluorescence microscope at 478 nm excitation and 507 nm emission wavelengths. Between 100 and 150 comets were scored per experiment and apoptotic cells were assigned based on their tail moments (20) .
Western blot
To prepare lysates, the cells were washed in PBS and solubilized with 50 mM Hepes solution (pH 7. 
Electrophoretic mobility shift assays (EMSA)
Nuclear extracts were prepared as previously described (21) . For EMSA, the binding reactions were performed for 20 min in 5 mM Tris-HCl (pH 7.5), 37.5 mM KCl, 4% (w/v) Ficoll 400, 0.2 mM EDTA, 0.5 mM DTT, 1 µg poly(dI-dC) . poly(dI-dC), 0.25 ng (>20,000cpm) 32 Plabeled double stranded oligonucleotide, and 2 µg protein of nuclear extract. Electrophoresis of samples through a native 6% polyacrylamide gel will be followed by autoradiography. The double stranded EMSA probes used in the present study include an oligonucleotide with two GATA consensus elements 5'-CAC TTG ATA ACA GAA AGT GAT AA CT CT-3', the proximal 250 bp region of the gata4 promoter, and an oligonucleotide containing the sequence from positions -95 to -55 of the gata4 promoter. Supershift experiments were performed by incubating nuclear extracts with 2 µg of antibodies for Egr1, Sp1, USF1 and USF2 (Santa Cruz Biotechnology).
Reverse transcription-polymerase chain reaction (RT-PCR)
Total RNA (1 µg) extracted using TRIZOL (Invitrogen, Carlsbad, CA) was reversetranscribed by oligo(dT) priming and MMLV reverse transcriptase (Applied Biosystems, Foster City, CA). The resultant cDNA was amplified using Taq DNA polymerase (Invitrogen) and resolved on a 1.5% agarose gel containing ethidium bromide. Two sets of PCR primers for human GATA-4 were designed and used in this study to confirm the expression of gata4 mRNA. 
Transfection and luciferase assays
The day before transfection, cells were plated at 1. 
5' Rapid Amplification of cDNA Ends (5' RACE)
Total RNA was isolated from the C57BL/6 mouse heart by TRIzol (Invitrogen).
Antisense primer (5'-CAG CAT CAA AGC AGA AAC-3') located within exon 2 was used for first-strand synthesis. Subsequent amplification was performed using the 5' RACE System for Amplification of cDNA Ends (Invitrogen). In brief, first strand cDNA was tailed with recombinant TdT and linker (dC) oligonucleotide. 5' RACE was performed by incubating with an aliquot of RACE primer located upstream of anti-sense primer (5'-AGG CTC TGG TTT GCT CAG GAA AAA-3') and with Abridged Anchor Primer (AAP) using Platinum Taq HighFidelity DNA polymerase (Invitrogen). Subsequently, nested PCR was performed with a nested primer designed upstream of RACE primer (5'-CCA AAT TGG ATT TGC GGT TGC T-3') and
Abridged Universal Amplification Primer (AUAP). The nested primer was used to sequence the PCR product to determine the transcriptional start site.
Cloning of gata4 gene promoter
Fragments containing proximal 1,000 bp, 500 bp, and 250 bp regions of the gata4 gene promoter were cloned by PCR cloning using mouse genomic DNA obtained from Promega inserts were screened by digestion and subjected to bidirectional sequencing.
Statistical analysis
Means + S.E. were calculated. Significant differences between all groups were computed by one-way analysis of variance using an F statistics. Statistically significant differences between two groups were determined by the Student's t-test.
Results
Effects of mediators of pulmonary vascular remodeling on Bcl-x L gene expression
To determine if Bcl-x L expression is regulated in remodeled pulmonary artery smooth muscle in vivo, rats were subjected to 2, 7 or 14 days of chronic hypoxia (10% O 2 ) to induce pulmonary hypertension. In these rats, we noted significant increase in the mass of right ventricle/(left ventricle + septum) as early as 7 days of chronic hypoxia, indicating increased pulmonary vascular resistance and resultant right ventricular hypertrophy (Fig. 1A) . Pulmonary vascular thickening was evident by 14 days of chronic hypoxia (Fig. 1B) . In these remodeled pulmonary arteries, increased Bcl-x L expression was observed by Western blot (Fig. 1C ).
Histological analyses also revealed an increased expression of Bcl-x L protein in the lung of rats treated with 14 days of chronic hypoxia (Fig. 1D) , showing enhanced Bcl-x L expression in pulmonary arteries as well as surrounding lung structures. These results demonstrate in vivo that pulmonary vascular remodeling is associated with increased expression of anti-apoptotic Bcl-x L .
Vasoactive agents such as 5-HT and ET-1 also induce pulmonary artery SMC proliferation and are thought to play important roles in promoting pulmonary vascular remodeling (23, 24) . We found that these agents can also increase Bcl-x L gene expression. The
bcl-x promoter is controlled by complex mechanisms, which utilize alternative promoters regulating anti-apoptotic Bcl-x L , pro-apoptotic Bcl-x S and other isoforms (25) . The luciferase construct, pGL2-0.6R (22) , contains a 0.6 kb fragment within the P1/P2 region of the bcl-x promoter (25) with regulatory sites for specifically expressing anti-apoptotic isoform Bcl-x L . As shown in Fig. 1E , treatment of cells with 5-HT or ET-1, but not hypoxia, promoted luciferase reporter gene expression controlled by the 0.6 kb proximal region of the bcl-x promoter.
Western blot also shows the Bcl-x L protein expression being enhanced by 5-HT or ET-1 (Fig.   1F ). These results demonstrate that 5-HT and ET-1, which have been shown to elicit signal transduction for cell proliferation, also promote gene transcription of anti-apoptotic Bcl-x L in pulmonary artery SMC.
To confirm the anti-apoptotic functions of Bcl-x L in pulmonary artery SMC, adenovirus expressing human Bcl-x L was constructed and the effects of Bcl-x L overexpression on cell death were studied. Enhanced expression of Bcl-x L via adenovirus-mediated gene transfer in BPASMC effectively attenuated the ability of SNP to induce cell death ( Fig. 2A) . SNP also caused the disruption of mitochondrial membrane potential, an early event of apoptosis, as indicated in green color in Fig. 2B . These effects of SNP on mitochondrial membrane potential were almost completely prevented by the overexpression of Bcl-x L , demonstrating a functional role of Bcl-x L in regulating pulmonary artery SMC apoptosis. Further, the apoptosis of pulmonary artery SMC induced by agents such as SNAP and DNR was attenuated by 5-HT or ET-1 (Fig. 2C) , which activates Bcl-x L . Collectively, these results demonstrate that pulmonary vascular remodeling is associated with increased expression of Bcl-x L which can indeed serve as an anti-apoptotic factor in pulmonary artery SMC. Thus, suppressing this anti-apoptotic protein might be a way to induce apoptosis for regressing pulmonary vascular thickening.
SNP downregulates the expression of anti-apoptotic protein Bcl-x L
The ability of NO donors to induce apoptosis of pulmonary artery SMC (26-28) might play important roles in their beneficial effects observed in pulmonary hypertension patients (29) (30) (31) (32) ). Thus, we tested the hypothesis that an NO donor, SNP, might reduce the expression of Bclx L expression, particularly in the remodeled pulmonary artery. Rats were subjected to chronic hypoxia for 2 wks to induce pulmonary vascular thickening and the organ culture of isolated pulmonary vessels was treated with SNP. RT-PCR analysis of RNA obtained from these preparations revealed the expression of bcl-x L mRNA that was decreased by the SNP treatment (Fig. 3A) . Similarly, a treatment of BPASMC with 100 µM SNP for 24 h resulted in decreased expression of Bcl-x L protein (Fig. 3B ).
To determine whether the downregulated Bcl-x L protein expression is due to suppressed gene transcription, effects of SNP on the bcl-x L promoter activity were studied. Using the luciferase reporter construct with the 0.6 kb bcl-x promoter, we found that SNP inhibited the transcriptional activity. As shown in Fig. 3C , transfection of BPASMC with the bcl-x promotercontrolled reporter vector increased firefly luciferase activity that was apparent by 24 h and peaked at 48 h. Treatment with SNP suppressed this activity. Cells were co-transfected with thymidine kinase promoter-controlled Renilla luciferase reporter construct to assess the specificity of SNP actions to the bcl-x promoter. The ratio of the bcl-x promoter activity to thymidine kinase promoter activity was decreased by 70% with 150 µM SNP and 90% with 300 µM SNP (Fig. 3D) . These results suggest that SNP inhibits Bcl-x L gene expression by modulating the activity of the 0.6 kb promoter region.
SNP downregulates GATA DNA binding activity
The 0.6 kb region of the bcl-x promoter contains two GATA consensus motifs (22) , and a recent study in cardiac muscle cells identified that these two sites are regulated by GATA-4 (33).
We have previously reported that BPASMC express GATA binding factors including GATA-4.
Further, mediators of pulmonary hypertension and inducers of pulmonary artery SMC growth such as 5-HT and ET-1 activate GATA-4 DNA binding (21) . Treatment of BPASMC with SNP caused dose-dependent suppression of GATA DNA binding activity (Fig. 4A) . Densitometry analysis demonstrated that a treatment of BPASMC with 300 µM SNP for 20 h resulted in a 90% reduction in GATA activity. SNP also inhibited the GATA-binding activity in HPASMC, which also contain GATA-4 (data not shown).
To determine whether GATA-4 is involved in the regulation of Bcl-x L expression, effects of ectopic expression of GATA-4 were tested. Adenovirus-mediated gene transfer of wild-type GATA-4 increased the GATA-4 protein expression and GATA DNA binding activity in BPASMC. SNP had no effects on ectopically induced GATA activity (data not shown). We found that the overexpression of GATA-4 via adenovirus-mediated gene transfer attenuated SNP-induced suppression of Bcl-x L (Fig. 4B) . These results provide direct evidence for the role of GATA in SNP-induced downregulation of Bcl-x L .
We next investigated the mechanisms of GATA downregulation induced by SNP in pulmonary artery SMC. In HPASMC, the expression of gata4 mRNA was confirmed by RT-PCR experiments using PCR primers derived from the known human mRNA sequence. Further, downregulation of the GATA activity by SNP appears to be due to decreased expression of GATA-4, as the mRNA expression of gata4 was suppressed to 50% of control by 1 h and to <10% by 4 h in response to treatment with 100 µM SNP (Fig. 4C) . In organ culture of remodeled rat pulmonary artery, SNP was also found to effectively reduce gata4 mRNA expression (Fig. 4D) .
SNP suppresses gata4 gene transcription
To determine whether the inhibitory effects of SNP on GATA-4 expression is regulated at the level of gata4 gene transcription, we first identified the transcriptional start site and then cloned the 1,000 bp mouse gata4 promoter into the pGL3 luciferase vector. This promoter region is directly upstream from the transcriptional start site that is 4.1 kb upstream from the translational start site as determined by the 5'-Rapid Amplification of cDNA Ends (RACE) analysis (Fig. 5A) , and shares 90% homology with the promoter of the rat gata4 gene.
Transfection of this luciferase construct in BPASMC resulted in expression of firefly luciferase within 24 h after transfection. The activity of this gata4 promoter fragment was suppressed by treating cells with SNP (Fig. 5B) .
To examine the site of gata4 promoter, which might be responsible for SNP-induced inhibition of gata4 promoter-dependent gene transcription, the 1,000 bp region was further truncated to 500 and 250 bp fragments. We found that truncation of the 1,000 bp region did not significantly alter the basal transcriptional activity (Fig. 5C ), suggesting that 250 bp proximal region contains important regulatory elements for the basal expression of GATA-4 in pulmonary artery SMC. We found that SNP similarly affected gene transcription controlled by the 1,000, 500 and 250 bp regions (Fig. 5D) , suggesting that the SNP-target site might reside within the proximal 250 bp region of the gata4 promoter. Thus, SNP appears to affect the proximal 250 bp region, suppress GATA-4 expression, and in turn inhibit gene transcription of Bcl-x L .
To identify transcription factors, which regulate the proximal 250 bp region of the gata4 promoter, supershift experiments were performed using antibodies against putative binding factors. As shown in Fig. 6A , the proximal 250 bp region of the gata4 promoter contains an early growth response 1 (Egr1)/specificity protein 1 (Sp1) overlapping site as well as binding sites for upstream stimulating factors (USF). Results showed that antibodies against Egr1, USF1
and USF2 supershifted the band (Fig. 6B) , suggesting the binding of these transcription factors to the proximal 250 bp region of the gata4 promoter.
To further examine the role of these factors in the regulation of gata4 gene transcription, a shorter 40 bp EMSA probe, which contains the sequence from -55 to -95 within the gata4 promoter, was constructed. We found a band that is supershifted by antibodies against Egr1, USF1 and USF2 in EMSA experiments using BPASMC nuclear extracts and this shorter 40 bp EMSA probe. We found that this band was increased in response to treating BPASMC with SNP (Fig. 6C) . These results led us to hypothesize that one or more factors binding to this region of the gata4 promoter might serve as negative regulators of gata4 gene transcription. We found that the mutation of the USF binding sites inhibited gata4 promoter activity (Fig. 6D ),
indicating the importance of USF1/USF2 in the basal expression of gata4. Further, overexpression of wild-type Egr1 inhibited the gata4 promoter activity (Fig. 6E) , providing evidence that the increased Egr1 binding might lead to suppressed gata4 gene transcription.
Discussion
In the present study, we found that the expression of anti-apoptotic Bcl-x L is increased by the mediators of pulmonary hypertension. In the in vivo rat model of chronic hypoxia, Values represent means ± S.E. of percent of the ratio of pGATA4-luciferase and pTK luciferase activities relative to untreated controls. 
